X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs WOCKHARDT LTD. - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE WOCKHARDT LTD. CADILA HEALTHCARE/
WOCKHARDT LTD.
 
P/E (TTM) x 32.1 -15.1 - View Chart
P/BV x 6.0 2.5 241.1% View Chart
Dividend Yield % 0.8 1.3 59.2%  

Financials

 CADILA HEALTHCARE   WOCKHARDT LTD.
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
WOCKHARDT LTD.
Mar-17
CADILA HEALTHCARE/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs4601,129 40.7%   
Low Rs305627 48.6%   
Sales per share (Unadj.) Rs92.1363.1 25.4%  
Earnings per share (Unadj.) Rs14.8-20.4 -72.5%  
Cash flow per share (Unadj.) Rs18.5-7.0 -264.9%  
Dividends per share (Unadj.) Rs3.2010.00 32.0%  
Dividend yield (eoy) %0.81.1 73.5%  
Book value per share (Unadj.) Rs68.0301.8 22.5%  
Shares outstanding (eoy) m1,023.74110.55 926.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.22.4 171.8%   
Avg P/E ratio x25.8-42.9 -60.1%  
P/CF ratio (eoy) x20.7-125.9 -16.4%  
Price / Book Value ratio x5.62.9 193.4%  
Dividend payout %21.6-48.9 -44.2%   
Avg Mkt Cap Rs m391,58197,063 403.4%   
No. of employees `00016.96.8 249.0%   
Total wages/salary Rs m15,0029,665 155.2%   
Avg. sales/employee Rs Th5,594.55,931.8 94.3%   
Avg. wages/employee Rs Th890.11,428.1 62.3%   
Avg. net profit/employee Rs Th899.9-334.0 -269.4%   
INCOME DATA
Net Sales Rs m94,29540,146 234.9%  
Other income Rs m1,2861,143 112.6%   
Total revenues Rs m95,58141,289 231.5%   
Gross profit Rs m19,036128 14,871.9%  
Depreciation Rs m3,7501,489 251.8%   
Interest Rs m4502,253 20.0%   
Profit before tax Rs m16,122-2,472 -652.3%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,289-211 -610.6%   
Profit after tax Rs m15,168-2,260 -671.0%  
Gross profit margin %20.20.3 6,331.7%  
Effective tax rate %8.08.5 93.6%   
Net profit margin %16.1-5.6 -285.7%  
BALANCE SHEET DATA
Current assets Rs m60,22346,160 130.5%   
Current liabilities Rs m53,05819,258 275.5%   
Net working cap to sales %7.667.0 11.3%  
Current ratio x1.12.4 47.4%  
Inventory Days Days70101 69.3%  
Debtors Days Days8894 93.7%  
Net fixed assets Rs m72,98440,165 181.7%   
Share capital Rs m1,024553 185.3%   
"Free" reserves Rs m68,57632,814 209.0%   
Net worth Rs m69,60033,367 208.6%   
Long term debt Rs m24,68431,903 77.4%   
Total assets Rs m152,20789,687 169.7%  
Interest coverage x36.8-0.1 -37,915.6%   
Debt to equity ratio x0.41.0 37.1%  
Sales to assets ratio x0.60.4 138.4%   
Return on assets %10.30 -119,516.8%  
Return on equity %21.8-6.8 -321.7%  
Return on capital %17.9-0.3 -5,349.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m21,2809,121 233.3%   
Fx outflow Rs m10,8742,133 509.8%   
Net fx Rs m10,4066,988 148.9%   
CASH FLOW
From Operations Rs m13,495-2,695 -500.8%  
From Investments Rs m-29,103-6,863 424.1%  
From Financial Activity Rs m23,15812,545 184.6%  
Net Cashflow Rs m7,5563,010 251.0%  

Share Holding

Indian Promoters % 74.8 74.5 100.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 2.3 360.9%  
FIIs % 5.9 7.7 76.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 11.0 15.4 71.4%  
Shareholders   44,069 67,757 65.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   BIOCON LTD  GLENMARK PHARMA  AUROBINDO PHARMA  PLETHICO PHARMA  TTK HEALTHCARE  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and FMCG sector witnessing maximum buying interest.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 21, 2018 01:05 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS